Posted in Health & Safety

AU: ‘Aggressive, Bold’ Action Needed to Combat COVID-19 in Africa

The African Union says “aggressive and bold” action is needed to combat the COVID-19 outbreak on the continent. More than one million cases of the…

Continue Reading AU: ‘Aggressive, Bold’ Action Needed to Combat COVID-19 in Africa
Posted in Health & Safety

Marikana police station temporarily closed due to Covid-19 positive case

NORTH WEST – All communities being serviced by the Marikana police station are advised that this police station is currently closed due to one of…

Continue Reading Marikana police station temporarily closed due to Covid-19 positive case
Posted in Press Releases

Première biopsie liquide à recevoir l’approbation de la FDA pour le profilage complet des tumeurs dans tous les cancers solides, le diagnostic compagnon Guardant360® de Guardant Health gagne en crédibilité auprès des oncologues en Asie, au Moyen-Orient et en Afrique.

SINGAPOUR, 8 août 2020 /PRNewswire/ — La Food and Drug Administration (FDA) des États-Unis a approuvé la biopsie liquide de Guardant Health, le diagnostic compagnon Guardant360®, pour le profilage des mutations tumorales chez les patients atteints de toutes sortes de cancers solides. Pour Guardant Health Asia, Middle East and Africa (AMEA), cette approbation de la FDA […]

Continue Reading Première biopsie liquide à recevoir l’approbation de la FDA pour le profilage complet des tumeurs dans tous les cancers solides, le diagnostic compagnon Guardant360® de Guardant Health gagne en crédibilité auprès des oncologues en Asie, au Moyen-Orient et en Afrique.
Posted in Press Releases

First liquid biopsy to receive FDA Approval for comprehensive tumor profiling across all solid cancers, Guardant Health’s Guardant360® CDx, gains credibility among oncologists in Asia, Middle East and Africa.

SINGAPORE, Aug. 8, 2020 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Guardant Health’s liquid biopsy, Guardant360® CDx, for tumor mutation profiling in patients across all solid cancers. For Guardant Health Asia, Middle East and Africa (AMEA), this FDA approval represents a landmark achievement for the Guardant360 test. Currently, the liquid biopsy is […]

Continue Reading First liquid biopsy to receive FDA Approval for comprehensive tumor profiling across all solid cancers, Guardant Health’s Guardant360® CDx, gains credibility among oncologists in Asia, Middle East and Africa.
Posted in Press Releases

First liquid biopsy to receive FDA Approval for comprehensive tumor profiling across all solid cancers, Guardant Health’s Guardant360® CDx, gains credibility among oncologists in Asia, Middle East and Africa.

SINGAPORE, Aug. 8, 2020 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Guardant Health’s liquid biopsy, Guardant360® CDx, for tumor mutation profiling in patients across all solid cancers. For Guardant Health Asia, Middle East and Africa (AMEA), this FDA approval represents a landmark achievement for the Guardant360 test. Currently, the liquid biopsy is […]

Continue Reading First liquid biopsy to receive FDA Approval for comprehensive tumor profiling across all solid cancers, Guardant Health’s Guardant360® CDx, gains credibility among oncologists in Asia, Middle East and Africa.